Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target

Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target

Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.

Why E2open Stock Is Falling After Hours

By Ryan Gustafson

October 10, 4:48 PM

E2open Parent Holdings Inc (NYSE: ETWO) shares are trading lower in Tuesday's after-hours session after the company reported second-quarter earnings.

ETWO

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $401

By Benzinga Newsdesk

July 29, 7:50 AM

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $375 to $401.

ARGX

Harmonic Appoints Walter Jankovic As Chief Financial Officer, Effective Immediately

By Benzinga Newsdesk

May 22, 4:08 PM

Harmonic Inc. (NASDAQ:HLIT) today announced that it has appointed Walter Jankovic as chief financial officer, effective immediately. Mr. Jankovic brings over 30 years of executive experience from a range of leading

HLIT

Nasdaq Surges Over 200 Points; Aaron’s Shares Jump

By Avi Kapoor

June 17, 2:40 PM

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on…

AAN

Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target

Related Posts

Why E2open Stock Is Falling After Hours

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $401

Harmonic Appoints Walter Jankovic As Chief Financial Officer, Effective Immediately

Nasdaq Surges Over 200 Points; Aaron’s Shares Jump